Growth hormone treatment improves final height in children with X-linked hypophosphatemia

BACKGROUND/AIM: Despite optimal conventional treatment (oral phosphate supplements and active vitamin D analogs), about 40–50% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, making them less likely to achieve an acceptable final height. Here, we studied...

Descripción completa

Detalles Bibliográficos
Autores principales: André, Julia, Zhukouskaya, Volha V., Lambert, Anne-Sophie, Salles, Jean-Pierre, Mignot, Brigitte, Bardet, Claire, Chaussain, Catherine, Rothenbuhler, Anya, Linglart, Agnès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768884/
https://www.ncbi.nlm.nih.gov/pubmed/36544157
http://dx.doi.org/10.1186/s13023-022-02590-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768884/
https://www.ncbi.nlm.nih.gov/pubmed/36544157
http://dx.doi.org/10.1186/s13023-022-02590-5

Ejemplares similares